NFKB1 and neoplasm: IKK inhibitors and proteasome inhibitors can suppress the nuclear translocation of NF-κB either directly or indirectly, leading to the downregulation of inflammatory cytokines (e.g., TNF-α, IL-6) and anti-apoptotic genes, thereby contributing to tumor microenvironment modulation.